Pertuzumab biosimilar (Shanghai Henlius Biotech)

帕妥珠单抗生物类似药（上海复宏汉霖）

Report date: 2026/05/28 20:00:21

Base Information

Drug NamePertuzumab biosimilar (Shanghai Henlius Biotech)
Drug Alias Name重组抗HER2结构域II人源化单克隆抗体Pertuzumab-DPZBPOHERDYHLX-11
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/11/13
Country/TerritoryBulgariaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdOrganon LLCShanghai Henlius Biotech Inc +[5] 
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeL01XC13
Related LinksN/A